GlassScriptPhysician profile
Marwan Mohamed Ali
NPI 1477915775
$12,601.09
in general payments reported to CMS, 2019-2025
26 companies · $3,113 in 2025
The $3,113 reported for 2025 was more than what 87% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $247 · 2021: $166 · 2022: $2,469 · 2023: $2,144 · 2024: $3,000 · 2025: $3,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,488 · Travel and Lodging: $2,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,488.06 |
| Travel and Lodging | $2,768.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,149.44 | 2019-2025 | General - Erectile Dysfunction, Ams 700, Ams 700 Cxr Rte Kit |
| Coloplast Corp | $4,557.77 | 2022-2025 | Titan |
| Endo USA, INC. | $442.87 | 2024-2025 | Xiaflex |
| Teleflex LLC | $228.54 | 2025 | Barrigel, Urolift |
| Procept Biorobotics Corporation | $165.20 | 2024-2025 | Aquabeam System |
| Tolmar, INC. | $153.19 | 2023-2024 | |
| Calyxo, INC. | $140.65 | 2024 | Cvac Aspiration System |
| Ferring Pharmaceuticals INC. | $122.70 | 2024-2025 | Adstiladrin |
| Axonics, INC. | $114.75 | 2023 | Axonics |
| Antares Pharma, INC. | $86.97 | 2022-2025 | Xyosted |
| Pfizer INC. | $67.54 | 2024 | |
| Endo Pharmaceuticals INC. | $52.29 | 2021 | |
| Abbvie INC. | $45.44 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.02 | 2024 | |
| Innovation Technologies INC | $29.17 | 2025 | Irrisept |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $24.34 | 2023 | Exparel, Iovera |
| Azurity Pharmaceuticals, INC. | $23.86 | 2025 | Azmiro |
| Urogen Pharma, INC. | $22.59 | 2024 | |
| Medtronic USA, INC. | $21.96 | 2019 | |
| Telix Pharmaceuticals | $20.28 | 2024 | Illuccix |
| Laborie Medical Technologies Corp. | $20.13 | 2025 | |
| Angiodynamics, INC. | $19.62 | 2025 | Nanoknife |
| Sumitomo Pharma America, INC. | $16.89 | 2024 | Orgovyx |
| Astellas Pharma US INC | $14.97 | 2025 | Veozah |
| Olympus America INC. | $13.83 | 2025 | Itind System |
| Novartis Pharmaceuticals Corporation | $13.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marwan Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.